Effect of Experience Sharing and Mutual Assistance on Insight and Recovery During the First Psychotic Episode

NCT ID: NCT06263933

Last Updated: 2024-02-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-13

Study Completion Date

2025-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Controlled, prospective, qualitative and quantitative trial. The goal of this trial is to evaluate the mutual assistance early intervention device efficacy and its impact on insight and personal recovery of participants living with a first psychotic episode. This intervention lasts 5 days with 1 session per day of 1 hour 30 minutes. Three evaluations, before the intervention, after intervention and 1 month after the hospitalization's end.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychotic Episode

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

A control group and a intervention group
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Patients are followed in routine care.

Group Type SHAM_COMPARATOR

Insight Scale

Intervention Type OTHER

Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group

Semi-directional interviews

Intervention Type OTHER

In the end of the intervention. In the end of DIPEM Or in the end of control group.

This intervention will be held after one month of hospitalization.

routine care

Intervention Type OTHER

routine care

DIPEM group

Patients have 5 session of mutual assistance with a mediator psychologist, during five days, with 1 session per day. Each session lasts 1h30, with 45 min for atelier, 15 min for pause and 30 min about collective discussion.

Group Type EXPERIMENTAL

Insight Scale

Intervention Type OTHER

Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group

Semi-directional interviews

Intervention Type OTHER

In the end of the intervention. In the end of DIPEM Or in the end of control group.

This intervention will be held after one month of hospitalization.

session of mutual assistance with a mediator psychologist

Intervention Type OTHER

session of mutual assistance with a mediator psychologist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insight Scale

Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group

Intervention Type OTHER

Semi-directional interviews

In the end of the intervention. In the end of DIPEM Or in the end of control group.

This intervention will be held after one month of hospitalization.

Intervention Type OTHER

routine care

routine care

Intervention Type OTHER

session of mutual assistance with a mediator psychologist

session of mutual assistance with a mediator psychologist

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

stage of recovery scale

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman between 18 and 40 years old
* First psychotic episode under the guidance of a doctor
* Brief psycotic trouble (SM-V)
* Presenting a first psychiatry hospitalization (all modalities hospitalizations combined)
* Fluent in French language (read and written)
* Patient affiliated to a social protection system or beneficiary of Medical Aid of State
* Patient having signed informed consent for his participation in the protocol

Exclusion Criteria

* Patients whose clinical condition does not allow them to participate in research
* Patients placed in isolation rooms during the intervention
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre hospitalier de Ville-Evrard, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dominique JANUEL

head of research center and clinical professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Etablissement Public de Santé de Ville-Evrard

Neuilly-sur-Marne, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rusheenthira Thavaseelan

Role: CONTACT

0143093232 ext. 033

mathilde Pistre

Role: CONTACT

0143093232 ext. 033

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rusheenthira Thavaseelan

Role: primary

0143093232 ext. 033

Dominique Januel

Role: backup

0143093232 ext. 033

References

Explore related publications, articles, or registry entries linked to this study.

Andresen R, Oades L, Caputi P. The experience of recovery from schizophrenia: towards an empirically validated stage model. Aust N Z J Psychiatry. 2003 Oct;37(5):586-94. doi: 10.1046/j.1440-1614.2003.01234.x.

Reference Type BACKGROUND
PMID: 14511087 (View on PubMed)

Courtet P. [Suicidal risk during the first psychotic episode]. Encephale. 2018 Dec;44(6S):S39-S43. doi: 10.1016/S0013-7006(19)30078-8. French.

Reference Type BACKGROUND
PMID: 30935486 (View on PubMed)

Fennig S, Kovasznay B, Rich C, Ram R, Pato C, Miller A, Rubinstein J, Carlson G, Schwartz JE, Phelan J, et al. Six-month stability of psychiatric diagnoses in first-admission patients with psychosis. Am J Psychiatry. 1994 Aug;151(8):1200-8. doi: 10.1176/ajp.151.8.1200.

Reference Type BACKGROUND
PMID: 8037256 (View on PubMed)

Franck N. [How to involve patients with schizophrenia in their treatment using psychoeducation]. Presse Med. 2016 Sep;45(9):742-8. doi: 10.1016/j.lpm.2016.07.012. Epub 2016 Aug 12. French.

Reference Type BACKGROUND
PMID: 27526987 (View on PubMed)

Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007 Jul;20(4):359-64. doi: 10.1097/YCO.0b013e32816ebc8c.

Reference Type BACKGROUND
PMID: 17551351 (View on PubMed)

Malla A, McGorry P. Early Intervention in Psychosis in Young People: A Population and Public Health Perspective. Am J Public Health. 2019 Jun;109(S3):S181-S184. doi: 10.2105/AJPH.2019.305018.

Reference Type BACKGROUND
PMID: 31242015 (View on PubMed)

Souaiby L, Gaillard R, Krebs MO. [Duration of untreated psychosis: A state-of-the-art review and critical analysis]. Encephale. 2016 Aug;42(4):361-6. doi: 10.1016/j.encep.2015.09.007. Epub 2016 May 6. French.

Reference Type BACKGROUND
PMID: 27161262 (View on PubMed)

Thompson KN, McGorry PD, Harrigan SM. Reduced awareness of illness in first-episode psychosis. Compr Psychiatry. 2001 Nov-Dec;42(6):498-503. doi: 10.1053/comp.2001.27900.

Reference Type BACKGROUND
PMID: 11704943 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A01804-41

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.